Antibody therapeutics firm, Kymab, raises $100m in series C funding round
Kymab, the Cambridge-based bio-pharmaceutical group developing treatments for diseases like HIV and malaria, secured $100m (£81m) in a recent series C investment round led by new investors ORI Fund. Also participating in the round were at least one business angel, Hepalink, and existing shareholders including Wellcome Trust, Bill & Melinda Gates Foundation, Malin Corporation plc, CF Woodford Equity Income Fund and Woodford Patient Capital plc, all of which have significant experience in the pharmaceutical field.
The series C follows the $120m series A and B financings.
The funds will enable Kymab to advance its proprietary pipeline of first-in-class therapeutic human monoclonal antibodies (those produced from a single line of identical cells), the first of which is commencing clinical development in 2017.
Read more here.